Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer

(2018) Ryan B. Corcoran et al.   Cancer Discovery

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

(2018) Fabiana Conciatori et al.   Cancers

Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes

(2018) Sebastian Mueller et al.   NATURE

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma

(2017) Coralie Dorard et al.   Nature Communications

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

(2017) Michele Milella et al.   Scientific Reports

Genetics and biology of pancreatic ductal adenocarcinoma

(2016) Haoqiang Ying et al.   GENES & DEVELOPMENT

Familial risk for lung cancer

(2016) Madiha Kanwal et al.   Oncology Letters

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

(2015) Ryan B. Corcoran et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

(2015) James Sherwood et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors

(2015) S. R. Whittaker et al.   MOLECULAR CANCER THERAPEUTICS

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma

(2015) Luigi Fattore et al.   Oncotarget

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

(2014) Piro Lito et al.   CANCER CELL

Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC

(2014) Ludovica Ciuffreda et al.   CURRENT PHARMACEUTICAL DESIGN

Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer

(2014) Sheila Piva et al.   CURRENT PHARMACEUTICAL DESIGN

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2014) S. Misale et al.   Science Translational Medicine

RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

(2014) Simona Lamba et al.   Cell Reports

Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells

(2013) Motoki Watanabe et al.   CANCER SCIENCE

Targeted therapy for melanoma: rational combinatorial approaches

(2013) L N Kwong et al.   ONCOGENE

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

MEK1/2 Inhibition Elicits Regression of Autochthonous Lung Tumors Induced by KRASG12D or BRAFV600E

(2012) C. L. Trejo et al.   CANCER RESEARCH

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms

(2012) Ludovica Ciuffreda et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies

(2012) Maria Rosaria Ricciardi et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

(2011) M. C. Garassino et al.   ANNALS OF ONCOLOGY

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

(2011) Leisl M. Packer et al.   CANCER CELL

c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

(2011) Rafael B. Blasco et al.   CANCER CELL

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

C-Raf Is Required for the Initiation of Lung Cancer by K-Ras G12D

(2011) Florian A. Karreth et al.   Cancer Discovery

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer

(2009) J. J. Yeh et al.   MOLECULAR CANCER THERAPEUTICS

BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins

(2008) B. B. Friday et al.   CANCER RESEARCH

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA